Phase 3 trial in 518 patients with HR-positive, HER2-positive metastatic breast cancer: adding palbociclib to maintenance anti-HER2 and endocrine therapy lengthened median PFS (44.3 vs 29.1 months; HR 0.75), with more grade 3 toxicity, mainly neutropenia.
RCTn = 518
Metzger et al. Palbociclib for Hormone-Receptor-Positive, HER2-Positive Advanced Breast Cancer